Delcath Systems, Inc. (NASDAQ:DCTH)
| Market Cap | 510.77M+29.5% |
| Revenue (ttm) | 95.42M+35.8% |
| Net Income | 532.00K-76.2% |
| EPS | 0.01-60.6% |
| Shares Out | 34.70M |
| PE Ratio | 1338.18 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 231,957 |
| Open | 15.23 |
| Previous Close | 15.32 |
| Day's Range | 14.70 - 15.41 |
| 52-Week Range | 8.12 - 17.42 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 24.50(+66.44%) |
| Earnings Date | Nov 3, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About DCTH
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
$DCTH stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in DCTH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DCTH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DCTH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
DCTH Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| HEPZATO KIT | $27.16M | 93.23% |
| CHEMOSAT | $1.97M | 6.77% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New DCTH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DCTH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DCTH
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $14.64M |
| IWMiShares Russell 2000 ETF | $11.45M |
| VXFVanguard Extended Market ETF | $5.03M |
| SURISimplify Propel Opportunities ETF | $3.46M |
| VTWOVanguard Russell 2000 ETF | $2.72M |
| DFASDimensional - US Small Cap ETF | $1.93M |
Estimated from each fund’s disclosed top holdings × AUM
DCTH Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DCTH’s recent data — informational, not investment advice